Tallarna and ABB Strengthen Strategic Partnership With Investment Deal
22.11.2022 14:00:00 EET | Business Wire | Press release
Tallarna, an award-winning climate tech company for the built environment, today announced that it has closed a strategic partnership and minority investment deal with ABB, a technology leader in electrification and automation. This signals a joint commitment to a software-led, risk-managed approach to accelerate net zero.
ABB’s solutions connect engineering know-how and software to optimise how things are manufactured, moved, powered, and operated. Building on more than 130 years of excellence, the company's expertise will be indispensable for the next stage of Tallarna’s growth.
Since launching four years ago, Tallarna has built a talented and loyal team, and has experienced wide-scale traction across the real estate sector – encompassing social housing providers, energy infrastructure developers, and green lenders. With ABB’s backing, the company’s scope will be extended to Energy Service Companies (ESCOs) serving commercial and industrial organisations.
Tallarna’s AI platform, KESTREL, makes decarbonisation projects a reality by aligning what can be achieved from an engineering perspective with what can be insured and funded. By finding the commonality between decision makers, the company opens the door to a new era of scalability. Tallarna’s software is integrated with the related underwriting processes of AmTrust Financial Services, a global specialty property and casualty insurer, who is also an existing investor. Together, the companies have created a unique Energy Savings Insurance product which enables customers to access project investors integrated into Tallarna’s platform.
As the climate and energy crisis grows, decision makers need the right tools to lower their emissions and operating costs. ABB’s deep knowledge of equipment performance and innovative electrification technology will enhance Tallarna’s existing capabilities. Coupling ABB products with performance insurance will give customers the confidence to action their sustainability journey.
“Never before has there been such a need for clear insights into decarbonisation possibilities and how to deliver them. Cross-industry collaboration is key to ensuring a sustainable future for all. As such, we are delighted to be working more closely with the Tallarna team and to support their launch in the ESCO market,” Giuseppe Casagrande, Global Digital Leader at ABB Electrification, Smart Power Division.
“As a company, our mission is to empower sustainability in all its forms – environmental, economic, and social. ABB shares this perspective, and we are excited to work with them on addressing the awareness, confidence, and execution gap facing customers,” Tim Meanock, CEO at Tallarna.
ABB’s investment and partnership will guide Tallarna in growing the market - taking decarbonisation to new heights for commercial, industrial, and energy infrastructure providers.
ESCO customers will benefit in 4 key ways:
-
Lower the barrier to entry for decarbonisation projects
Tallarna understands customers’ decarbonisation options using minimal data and, initially, without the need for connected devices. This capability will be augmented with ABB’s knowledge of innovative energy optimisation solutions in industrial settings.
-
Point a route to scale for customer projects
KESTREL translates engineering challenges into risk metrics and is used to underwrite and distribute Energy Savings Insurance. By adding ABB’s insights to this modelling, the companies will further mitigate risk while lowering costs and carbon emissions. Removing the performance risk from ESCOs and building owners encourages greater project scope and facilitates a service model, driving a route to scale.
-
Enable the market to move faster by overcoming barriers to execution
Guaranteed energy outputs can be financed, with the realised bill savings repaying the project costs. Not only does this deliver new funding sources for developers, but it creates financial assets for Tallarna’s panel of project investors. This provides a key mechanism for execution.
-
Ensure security of technology supply and performance
Tallarna can specify suitable technology products at the project exploration stage. These include offerings from a range of providers, including ABB. Technology is pre-validated for insurance and finance terms, and can be onboarded to provide security of supply, performance, and pricing.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005392/en/
Contact information
Michelle Taute
Senior Strategic Sustainability Lead
press@tallarna.com
+44 7771786102
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives European Union Approval for Restylane ® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping11.8.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today announced that Restylane Shaype has been approved in the EU under the Medical Device Regulation for temporary augmentation of the chin region. Engineered for deep injection to build and shape on bone, Restylane Shaype delivers a unique bone-mimicking effect, enabling immediate, natural-looking structural enhancement in the lower face without surgery.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810880899/en/ The lower face plays a pivotal role in overall facial balance, influencing proportions and profile.2 This region is an increasing area of concern for patients, with around one in four people expressing concerns related to lower face sagging and chin shape.5 When asked about their facial priorities, a third of people pointed out issues with their chin shape – a key contributor to facial definition and structural harmony.5 Genetic factors and age-related changes can lead to reduced chin d
Stonebranch is Again Named a Leader in the 2026 Gartner ® Magic Quadrant ™ for Service Orchestration and Automation Platforms (SOAPs)10.8.2026 18:00:00 EEST | Press release
Stonebranch, a leading provider of service orchestration and automation solutions, today announced that it has once again been positioned by Gartner as a Leader in the Magic Quadrant for Service Orchestration and Automation Platforms (SOAPs) for its offering, Universal Automation Center™ (UAC).1 “We’re pleased to be recognized as a Leader for the third year in a row,” said Giuseppe Damiani, CEO at Stonebranch. “To us, this recognition reflects our advancements in helping enterprises orchestrate increasingly complex IT operations with confidence. As organizations modernize their automation strategies and adopt AI, UAC provides the centralized orchestration control plane required to unify traditional automation with AI models and agentic systems. With built-in capabilities like Robi AI, UAC’s agentic copilot, we’re making it easier than ever for teams to build, manage, and optimize automation at enterprise scale.” Stonebranch UAC helps organizations unify, manage, and scale automation ac
Frontgrade Expands Huntsville Presence with Advanced R&D Center Supporting Next-Generation Space and Defense Missions10.8.2026 17:09:00 EEST | Press release
Frontgrade Technologies ("Frontgrade"), a leading provider of mission-critical electronics and integrated technologies, today announced the opening of its eighth U.S. location in Huntsville, Alabama. Located in Cummings Research Park, the new Advanced Research & Development Center will accelerate the development of next-generation mission processing technologies supporting critical space, defense, intelligence, and national security missions. The Huntsville center expands Frontgrade's engineering capabilities while placing research teams closer to customers, government organizations, industry partners, and leading academic institutions. By working within one of the nation's premier aerospace and defense ecosystems, Frontgrade will accelerate technology development, strengthen customer collaboration, and help deliver mission-ready capabilities faster. “Bringing Frontgrade’s capabilities to Huntsville is a meaningful milestone for me, both personally and professionally. For decades, this
Brightfin Appoints Preeti Shukla as Chief Product and AI Officer10.8.2026 16:00:00 EEST | Press release
Brightfin, the only IT Financial Management (ITFM) and Technology Expense Management solution built natively on ServiceNow, today announced the appointment of Preeti Shukla as Chief Product and AI Officer (CPAIO). In this newly created role, Shukla will lead product strategy and artificial intelligence across the Brightfin platform, advancing the company's mission to make every technology decision grounded in financial truth, operational clarity, and intelligent automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810283143/en/ Preeti Shukla, CPAIO of Brightfin Shukla brings two decades of experience building and scaling customer-facing, enterprise-grade B2B SaaS, fintech, and marketplace products across Fortune 100 companies and high-growth startups, including leadership roles at Workday and Oracle. A recognized authority on applied AI, she is a Gartner-recognized thought leader and author on AI SaaS and product en
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration10.8.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets. Clinical collaboration will explore potential targeted combination approaches for patients with RAS-addicted cancers Potential drug combinations for development as part of the clinical collaboration will include certain BeOne assets and Revolution Medicines’ four clinical RAS(ON) inhibitors: daraxonrasib, a RAS(ON) multi-selective inhibitor; zo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
